drugset
drugset / Trial / NCT03270956

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

NCT03270956 ↗

Phase 2 Completed 10 enrolled Prokidney CTI Clinical Trial and Consulting Services · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).

Timeline

Start
2018-04-25
Primary completion
2022-11-17
Completion
2022-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Renal Autologous Cell Therapy Unknown — —

Indications

chronic kidney disease type 2 diabetes mellitus